obrindatamab

Home
Ligands
obrindatamab

GtoPdb Ligand ID: 12586

Synonyms: (formerly orlotamab) | MGD-009 | MGD009

Comment: Obrindatamab (MGD009) is a bi-specific mAb-like agent that simultaneously targets the B7 immune regulator B7-H3 (CD276; expressed by many cancers and ) and CD3e (expressed by immune effector cells, and a negative regulator of T-cell activation with a role in immune-evasion, tumour cell invasion and metastasis), that was developed for anti-tumour potential [2]. The mechanism of obrindatamab is to promote the activation and cell-killing functions of immune effector cells and direct this towards the co-engaged tumour cells. Obrindatamab was developed using MacroGenics' proprietary Dual-Affinity Re-targeting (DART®) technology. The peptide sequences for the heavy and light chains of the B7-H3 binding domains of obrindatamab are claimed in MacroGenics' patent US8802091B2 9SEQ IDs 99 and 89 respectively) [1].

References
1. Johnson LS, Huang L, Moore PA, Loo DT, Chen FZ. (2014) Antibodies reactive with B7-H3 and uses thereof. Patent number: US8802091B2. Assignee: Macrogenics Inc. Priority date: 04/05/2012. Publication date: 12/08/2014.
2. Malapelle U, Parente P, Pepe F, Di Micco MC, Russo A, Clemente C, Graziano P, Rossi A. (2022) B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?. Int J Mol Sci, 23 (24). [PMID:36555714]

References

1. Johnson LS, Huang L, Moore PA, Loo DT, Chen FZ. (2014)
Antibodies reactive with B7-H3 and uses thereof.
Patent number: US8802091B2. Assignee: Macrogenics Inc. Priority date: 04/05/2012. Publication date: 12/08/2014.

2. Malapelle U, Parente P, Pepe F, Di Micco MC, Russo A, Clemente C, Graziano P, Rossi A. (2022)
B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?.
Int J Mol Sci, 23 (24). [PMID:36555714]